Trial reportPsycho-oncology2019
A randomized controlled trial of 24 weeks of varenicline for tobacco use among cancer patients: Efficacy, safety, and adherence.
Trial report in Psycho-oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 3 syntheses or guidelines pooled it, 39 citations in OpenAlex.
- Nicotine receptor partial agonists for smoking cessation.The Cochrane database of systematic reviews · 2023Pooled it
- Systematic Review of Smoking Cessation Interventions for Smokers Diagnosed with Cancer.International journal of environmental research and public health · 2022Pooled it
- Cessation classification likelihood increases with higher expired-air carbon monoxide cutoffs: a meta-analysis.Drug and alcohol dependence · 2021Pooled it
- Pilot Trial of a Behavioral Economics-Informed Clinical Decision Support Alert to Improve Inpatient Tobacco Use Treatment Rates.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2025Trial
- A qualitative study of attitudes and perceptions of smoking cessation medication among patients with cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Trial
- Scalable Telehealth Cancer Care: integrated healthy lifestyle program to live well after cancer treatment.Journal of the National Cancer Institute. Monographs · 2024Trial
- Efficacy and safety of combination behavioral activation for smoking cessation and varenicline for treating tobacco dependence among individuals with current or past major depressive disorder: A 2 × 2 factorial, randomized, placebo-controlled trial.Addiction (Abingdon, England) · 2023Trial
- Trial
- Placebo-controlled randomized clinical trial testing the efficacy and safety of varenicline for smokers with HIV.Drug and alcohol dependence · 2019Trial
- Protocol for the Mobile behavioral support plus varenicline for tobacco cessation among people living with HIV in India (MoVIe): A hybrid implementation-effectiveness randomized trial.Contemporary clinical trials · 2026Article
- Reach, Acceptability, and Effectiveness of Proactive Outreach and Varenicline with Cancer-Focused Counseling for Patients with Cancer: A Pilot Randomized Comparative Effectiveness Trial.JCO oncology advances · 2026Article
- Smoking Cessation and Mortality Risk in Cancer Survivorship: Real-World Data From a National Cancer Institute-Designated Cancer Center.Journal of the National Comprehensive Cancer Network : JNCCN · 2025Observational
- Early Treatment Engagement and Long-Term Smoking Abstinence Among Women With Cervical Intraepithelial Neoplasia or Cervical Cancer.AJPM focus · 2025Article
- Effective smoking cessation interventions in people with cancer: A systematic review and meta-analysis of randomized controlled trials.Tobacco prevention & cessation · 2025Review
- Effect of early medication adherence on behavioral treatment utilization and smoking cessation among individuals with current or past major depressive disorder.Addictive behaviors · 2024Article
- Evidence-Based Guideline for the Treatment of Smoking Cessation Provided by the National Health Insurance Service in Korea.Korean journal of family medicine · 2024Article
- Characterising the use of varenicline: an analysis of the Australian dispensing claims data.Addiction (Abingdon, England) · 2022Article
- Rationale and design of a randomized factorial clinical trial of pharmacogenetic and adherence optimization strategies to promote tobacco cessation among persons with HIV.Contemporary clinical trials · 2021Article
- It Takes Two to Tango: Patients' and Providers' Perspectives in Tobacco Cessation and Head/Neck Cancer.The oncologist · 2021Article
- Change in Health-Related Quality of Life Among Individuals With Cancer Undergoing Smoking Cessation Treatment Involving Varenicline.Oncology nursing forum · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 2 countries.
Funding
Abstract
objectiveContinuing to smoke after a cancer diagnosis undermines prognosis. Yet few trials have tested Food and Drug Administration (FDA)-approved tobacco use medications in this population. Extended use varenicline may represent an effective treatment for cancer patients who smoke given barriers to cessation including a prolonged time line for relapse.
methodsA placebo-controlled randomized trial tested 12 weeks of varenicline plus 12 weeks of placebo (standard [ST]) vs 24 weeks of varenicline (extended [ET]) with seven counseling sessions for treatment-seeking cancer patients who smoke (N = 207). Primary outcomes were 7-day biochemically confirmed abstinence at weeks 24 and 52. Treatment adherence and side effects, adverse and serious adverse events, and blood pressure were assessed.
resultsPoint prevalence and continuous abstinence quit rates at weeks 24 and 52 were not significantly different across treatment arms (P's > 0.05). Adherence (43% of sample) significantly interacted with treatment arm for week 24 point prevalence (odds ratio [OR] = 2.31; 95% confidence interval [CI], 1.15-4.63; P = 0.02) and continuous (OR = 5.82; 95% CI, 2.66-12.71; P < 0.001) abstinence. For both outcomes, adherent participants who received ET reported higher abstinence (60.5% and 44.2%) vs ST (44.7% and 27.7%), but differences in quit rates between arms were not significant for nonadherent participants (ET: 9.7% and 4.8%; ST: 12.7% and 10.9%). There were no significant differences between treatment arms on side effects, adverse and serious adverse events, and rates of high blood pressure (P's > 0.05).
conclusionsCompared with ST, ET varenicline does not increase patient risk and increases smoking cessation rates among patients who adhere to treatment. Studies are needed to identify effective methods to increase medication adherence to treat patient tobacco use effectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.